BiotechTube

0.5 mL of the low dose VAX-31 + 0.5 mL of the mid dose VAX-31 + 0.5 mL of the high dose VAX-31 + 0.5 mL dose of PCV20 + 0.5 mL of the High-PFS dose VAX-31

Phase 2Active
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pneumococcal Vaccines

Conditions

Pneumococcal Vaccines

Trial Timeline

Nov 25, 2024 → Dec 1, 2027

NCT ID
NCT06720038

About 0.5 mL of the low dose VAX-31 + 0.5 mL of the mid dose VAX-31 + 0.5 mL of the high dose VAX-31 + 0.5 mL dose of PCV20 + 0.5 mL of the High-PFS dose VAX-31

0.5 mL of the low dose VAX-31 + 0.5 mL of the mid dose VAX-31 + 0.5 mL of the high dose VAX-31 + 0.5 mL dose of PCV20 + 0.5 mL of the High-PFS dose VAX-31 is a phase 2 stage product being developed by VaxCyte for Pneumococcal Vaccines. The current trial status is active. This product is registered under clinical trial identifier NCT06720038. Target conditions include Pneumococcal Vaccines.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06720038Phase 2Active

Competing Products

20 competing products in Pneumococcal Vaccines

See all competitors
ProductCompanyStageHype Score
V116 + PPSV23MerckPhase 3
77
V114 + QIV + Matching Placebo for V114MerckPhase 3
77
V114 + Prevnar 13™ + PNEUMOVAX™23MerckPhase 3
77
V114 Lot 1 + V114 Lot 2 + Prevnar 13™MerckPhase 2
52
PNEUMOVAX™ 23MerckApproved
85
Pneumococcal Vaccine, Polyvalent (23-valent)MerckPhase 3
77
V114 + Prevnar 13™ + PNEUMOVAX™23MerckPhase 3
77
V114 + Prevnar 13®MerckPhase 3
77
V114 Medium Dose + V114 High Dose + V114 Medium Dose with Alternative Carrier Protein + V114 High Dose with Alternative Carrier Protein + Prevnar 13™MerckPhase 1/2
41
V116 + PPSV23MerckPhase 3
77
V114MerckPhase 3
77
Prevnar 13™ + V114 + RotaTeq™ + Pentacel™ + RECOMBIVAX HB™ + HIBERIX™ + M-M-R™ II + VARIVAX™MerckPhase 3
77
V114 + Prevnar 13®MerckPhase 3
77
Pneumococcal Conjugate Vaccine (V114) + PNEUMOVAX® 23 + PREVNAR 13®MerckPhase 2
52
V114-A + V114-B + Prevnar 13®MerckPhase 2
52
V116 + Pneumovax™23MerckPhase 1/2
41
V114 + Prevnar 13™MerckPhase 3
77
V114 + Prevnar 13™MerckPhase 2
52
Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®MerckApproved
85
21-valent pneumococcal conjugate vaccineMerckApproved
85

Other Products from VaxCyte

31-valent pneumococcal conjugate vaccine + Seasonal Influenza Vaccine (SIV) (Flublok) + PlaceboPhase 3
74
31 valent pneumococcal conjugate vaccine + PCV20 + PCV21Phase 3
74
31-valent pneumococcal conjugate vaccine + PCV20Phase 3
74
0.5 ml dose of 1.1 mcg VAX-24 + 0.5 ml dose of PCV20 + 0.5 ml dose of 2.2 mcg VAX-24 + 0.5 ml dose of 2.2/4.4 mcg VAX-24Phase 2
49
24-Valent Pneumococcal Conjugate Vaccine + Pneumococcal 20-valent Conjugate VaccinePhase 2
49